Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01419834
Recruitment Status : Recruiting
First Posted : August 18, 2011
Last Update Posted : December 27, 2017
Band of Parents
Y-mAbs Therapeutics
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : August 2018
  Estimated Study Completion Date : August 2018